Former M.D. Anderson president to retire from cancer center

The third president of the University of Texas M.D. Anderson Cancer Center will retire from the institution Aug. 31, a spokesperson confirmed to Houston Business Journal.   Dr. John Mendelsohn was the president of M.D. Anderson from 1996 to 2011 and remained a faculty member at the center as the director of Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, the spokesperson said. He is also a professor in M.D. Anderson’s department of g enomic medicine, per his profile…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Publication date: 1 January 2019Source: Materials Science and Engineering: C, Volume 94Author(s): Lijun You, Xiaocui Liu, Zhexiang Fang, Qianhui Xu, Qiqing ZhangAbstractA new folic acid (FA)-conjugated poly (lactic-co-glycolicacid) (PLGA)-polyethylene glycol (PEG) nano-noisome was prepared. The noisome was employed as a drug delivery system to load curcumin (Cur) as a model drug and fluorescent probe for cervical cancer therapy and cell imaging. The Fe3O4@PLGA-PEG@FA noisomes were prepared through facile emulsion solvent evaporation and conjugation chemistry method, possessing the properties of high rapid magnetic separati...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Authors: Mukherjee A, Waters AK, Babic I, Nurmemmedov E, Glassy MC, Kesari S, Yenugonda VM Abstract Antibody drug conjugates (ADC's) represent a promising and an efficient strategy for targeted cancer therapy. Comprised of a monoclonal antibody, a cytotoxic drug, and a linker, ADC's offer tumor selectively, reduced toxicity, and improved stability in systemic circulation. Recent approvals of two ADC's have led to a resurgence in ADC research, with more than 60 ADC's under various stages of clinical development. The therapeutic success of future ADCs is dependent on adherence to key requirements of their design and ...
Source: Human Antibodies - Category: Biochemistry Tags: Hum Antibodies Source Type: research
Conclusion: Although, the advanced cancer therapeutics have been established but the combination of different strategies is very important. The efficiency of the treatments depends on the stage of cancer and response of patients. Search for closely defined and selective molecular targets for a particular therapy is very complicated due to heterogenic nature of tumor environment, different therapeutic agents, incubation time, exposure doses and selectivity of therapy. The most promising photodynamic therapy (PDT) and multi- targeted therapies are being established but the question whether the cellular proteins that are most...
Source: Current Signal Transduction Therapy - Category: Molecular Biology Source Type: research
Publication date: December 2018Source: Biomedicine &Pharmacotherapy, Volume 108Author(s): Charlette Tiloke, Krishnan Anand, Robert M. Gengan, Anil A. ChuturgoonAbstractCancer is classified as one of the leading causes of global mortality. It has affected millions of people, often with poor prognosis. Having severe side-effects with conventional chemotherapy, alternate drugs and therapies are actively being investigated. There is a need for innovative drug discovery and design as existing cancer therapies are costly and not readily available. Ayurveda and traditional medicine have utilised natural resources such as plan...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Jason Roszik, Kari L. Ring, Khalida M. Wani, Alexander J. Lazar, Anna V. Yemelyanova, Pamela T. Soliman, Michael Frumovitz, Amir A. Jazaeri
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Authors: Nuryadi E, Sasaki Y, Hagiwara Y, Permata TBM, Sato H, Komatsu S, Yoshimoto Y, Murata K, Ando K, Kubo N, Okonogi N, Takakusagi Y, Adachi A, Iwanaga M, Tsuchida K, Tamaki T, Noda SE, Hirota Y, Shibata A, Ohno T, Tokino T, Oike T, Nakano T Abstract Radiotherapy is an essential component of cancer therapy. Despite advances in cancer genomics, the mutation signatures of radioresistant tumors have not yet been fully elucidated. To address this issue, we analyzed a unique set of clinical specimens from a uterine cervical cancer that repeatedly locally recurred after multiple rounds of radiotherapy. Exon sequencin...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
BioEssays, September 2018.
Source: BioEssays - Category: Molecular Biology Authors: Source Type: research
SummaryThe treatment of malignant tumors has considerably improved in recent years, and also the number of “long term cancer survivors” is increasing.The spectrum of anti-tumoral agents is increasing at a  fast pace and in addition to conventional therapies such as surgery, radiotherapy, and chemotherapy, new drugs with entirely new mechanisms are appearing. Side effects of old and new drugs can affect the central and peripheral nervous system, the neuromuscular junction, and muscle. These side effe cts often have to be distinguished from other causes and need neurological expertise. Although the majority ...
Source: Wiener Medizinische Wochenschrift - Category: General Medicine Source Type: research
In this study, a PEGylated iron MOF nanoparticle as a new and effective agent for Fenton cancer therapy method is reported. This stable nanoparticle, which can destroy cancer cells using the cells’ H2O2 does not have the issues such as low stability, high aggregation, and poor selectivity that have been reported for similar nanoparticles.
Source: Australian Journal of Chemistry - Category: Chemistry Authors: Source Type: research
I'm pleased to note that the Methuselah Fund has closed its first fundraising effort after hitting the target amount, obtaining the support of many long-standing members of our community. The fund is a mixed for-profit/non-profit vehicle that is intended to expand the investment efforts undertaken by the Methuselah Foundation in past years, helping promising lines of rejuvenation research to make the leap from laboratory to commercial development. At the present point in time there are few enough rejuvenation focused companies that doing this well requires extensive connections within the research community, and a willingn...
Source: Fight Aging! - Category: Research Authors: Tags: Activism, Advocacy and Education Source Type: blogs
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health Management | Men | Pharmaceuticals | Texas University